67
Participants
Start Date
March 10, 2010
Primary Completion Date
July 12, 2012
Study Completion Date
December 21, 2012
Cinacalcet
Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
Placebo
Administered orally following the same tiitration regimen as the experimental arm.
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Randwick
Research Site, St Leonards
Research Site, Footscray
Research Site, Geelong
Research Site, Nedlands
Research Site, Szeged
Research Site, New York
Research Site, Washington D.C.
Research Site, Morehead City
Research Site, Atlanta
Research Site, Jacksonville
Research Site, Pembroke Pines
Research Site, Miami
Research Site, Aventura
Research Site, Weston
Research Site, Clearwater
Research Site, Indianapolis
Research Site, Detroit
Research Site, Kenner
Research Site, New Orleans
Research Site, Aurora
Research Site, San Diego
Research Site, Lake Forest
Research Site, Mission Viejo
Research Site, Orange
Research Site, Lancaster
Research Site, Los Gatos
Research Site, Moscow
Research Site, Moscow
Research Site, Moscow
Research Site, Yaroslavl
Research Site, Saint Petersburg
Research Site, Rostov-na-Dony
Research Site, Columbus
Research Site, Calgary
Research Site, London
Research Site, Oakville
Research Site, Toronto
Research Site, Warsaw
Research Site, Warsaw
Research Site, Warsaw
Research Site, Coimbra
Research Site, Lisbon
Research Site, Lisbon
Lead Sponsor
Amgen
INDUSTRY